Prachi Arora

Employment

• Novo Nordisk (United States) Associate Director
  2024 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (17)

• Utilization outcomes of direct oral anticoagulants in Medicare patients
  Research in Social and Administrative Pharmacy 2023 DOI: 10.1016/j.sapharm.2023.07.002
  +Save
• Antibiotic prescribing trends in the US during the first 11 months of the COVID-19 pandemic
  Research in Social and Administrative Pharmacy 2022 DOI: 10.1016/j.sapharm.2022.05.008
  +Save
• Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants
  Journal of Comparative Effectiveness Research 2022 DOI: 10.2217/cer-2021-0307
  +Save
• A Cost-Effectiveness Study Comparing Ready-to-Administer and Traditional Vial-and-Syringe Method for Opioids
  Pain and Therapy 2022 DOI: 10.1007/s40122-022-00402-z
  +Save
• Impact of telehealth on health care resource utilization during the COVID-19 pandemic
  Journal of Comparative Effectiveness Research 2022 DOI: 10.2217/cer-2021-0242
  +Save
• Association between marijuana use and nonmedical prescription opioid use in the United States: are we shifting from one epidemic to another?
  Journal of Public Health Policy 2021 DOI: 10.1057/s41271-021-00282-1
  +Save
• A Continuous Observation Workflow Time Study to Assess Intravenous Push Waste
  Hospital Pharmacy 2021 DOI: 10.1177/0018578720931754
  +Save
• IMPACT OF TELEHEALTH UTILIZATION DURING THE COVID-19 PANDEMIC ON HEALTH CARE RESOURCE UTILIZATION
  Value in Health 2021
  +Save
• Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C
  Research in Social and Administrative Pharmacy 2020 DOI: 10.1016/J.SAPHARM.2019.08.026
  +Save
• Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin
  Expert Review of Pharmacoeconomics & Outcomes Research 2019 DOI: 10.1080/14737167.2017.1347041
  +Save